Evidence map›Paper›PMID 30747491›Full record

ArticleMolecular oncology2019

A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers.

Juan Miguel Baquero, Carlos Benítez-Buelga, Victoria Fernández, Miguel Urioste, Jose Luis García-Giménez, Rosario Perona, CIMBA Consortium, Javier Benítez, Ana Osorio

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Gene polymorphisms ofJournal of Cancer · 2024
    Article
  5. Review
  6. Somatic variants of potential clinical significance in the tumors ofHereditary cancer in clinical practice · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Juan Miguel BaqueroHuman Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID 0000-0002-6488-7742
Carlos Benítez-BuelgaHelleday Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
Victoria FernándezHuman Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Miguel UriosteSpanish Network on Rare Diseases (CIBERER), Madrid, Spain.
Jose Luis García-GiménezSpanish Network on Rare Diseases (CIBERER), Madrid, Spain.
Rosario PeronaSpanish Network on Rare Diseases (CIBERER), Madrid, Spain.
CIMBA ConsortiumConsortium of Investigators of Modifiers of BRCA1/2.
Javier BenítezHuman Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Ana OsorioHuman Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Spanish National Cancer Research Centre · ESInstituto de Investigaciones Biomédicas Sols-Morreale · ESKarolinska Institutet · SEUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single nucleotide polymorphisms (SNPs) in DNA glycosylase genes involved in the base excision repair (BER) pathway can modify breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We previously found that SNP rs34259 in the uracil-DNA glycosylase gene (UNG) might decrease ovarian cancer risk in BRCA2 mutation carriers. In the present study, we validated this finding in a larger series of familial breast and ovarian cancer patients to gain insights into how this UNG variant exerts its protective effect. We found that rs34259 is associated with significant UNG downregulation and with lower levels of DNA damage at telomeres. In addition, we found that this SNP is associated with significantly lower oxidative stress susceptibility and lower uracil accumulation at telomeres in BRCA2 mutation carriers. Our findings help to explain the association of this variant with a lower cancer risk in BRCA2 mutation carriers and highlight the importance of genetic changes in BER pathway genes as modifiers of cancer susceptibility for BRCA1 and BRCA2 mutation carriers.

Indexed as

Genetic Predisposition to DiseaseMutationPolymorphism, Single NucleotideBRCA2 ProteinFemaleHumansMiddle AgedOvarian NeoplasmsRisk FactorsUracil-DNA GlycosidaseBRCA2 ProteinBRCA2 protein, humanUracil-DNA GlycosidaseBRCA2cancer risk modifierDNA damageoxidative stress susceptibilitytelomere damageuracil-DNA glycosylase

Identifiers

PMID30747491
PMCPMC6487686
OpenAlexW2914796362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.